- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01100762
Transcranial Direct Current Stimulation (tDCS) and Parkinson's Disease
October 28, 2019 updated by: Gad Alon, University of Maryland, Baltimore
Can Transcranial Direct Current Stimulation (tDCS)Modulate Protective Stepping and Gait Performance of People With Parkinson's Disease
The use of low level electrical stimulation when applied over the head, also called transcranial direct current stimulation (tDCS), is being tested by several groups of researchers to see if tDCS can improve movements of persons with damage to the brain.
The safety and potential benefits of tDCS to children or adults patients who are paralyzed because of brain damage are reported in the medical literature.
In addition, some patients with Parkinson's disease (PD) experience improvement in memory and report better use of the hand after tDCS.
The treatment requires putting electrodes (pads) over the head and sending very small amount of electrical current that the patient may feel as "little tingling".
Application of tDCS takes 20 min.
In this study we wish to test if tDCS application can improve stepping and walking ability of subjects with PD and if the improvement is the same as when walking on treadmill.
We plan to test the subject's ability to step when pulled by a laboratory testing system and also test his/her walking ability.
There will be 3 sessions 7 days apart.
In the first session the subject will be tested then treated for 20 min with tDCS and then tested again.
In the second session the subject will be tested then walk on a treadmill for 20 min then tested again.
In the third session the subject will be tested then walk on the treadmill for 20 min while receiving also tDCS and tested one last time at the end of the session.
Each session will take between 2 and 3 hours.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Recent advances in non-invasive electrical stimulation technology including transcranial direct current stimulation (tDCS) have provided novel and low risk options to rehabilitate the impaired ability of the central nervous system (CNS) to process sensorimotor information.
Furthermore, tDCS appears to enhance CNS connectivity and there is preliminary evidence indicating that patients with Parkinson's Disease (PD) may experience improvement in working memory, the Unified Parkinson's Disease Rating Scale, simple reaction time and the Purdue Pegboard test.
tDCS is inexpensive, portable and available for repeated home use.
It may provide long-lasting enhancement of cortical activity in part because tDCS is easy to administer frequently and to combine it with other rehabilitation approaches including posture and gait training.
However to date, no study has examined quantitatively the effects of tDCS on posture control and walking ability in patients with PD.
As a first step we plan to identify the immediate effects of tDCS, as well as the added value of tDCS to treadmill exercise training, to improve posture and gait of individuals with PD.
Study Type
Interventional
Enrollment (Actual)
10
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- PTRS Research Lab
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diagnosis of adult onset of PD
- A history of freezing of gait (FOG) as evidence by clinical assessment
- A stable regimen of anti-parkinsonian medications
- Ability to walk at least 10m without assistance
- Ability to walk on a treadmill for 20 minutes
- Personal weight of less than 500 Lb (because the suspension harness over the treadmill is limited to 500 Lb
- Stage 3 of the Hoehn and Yahr disability scale
- A score of >24 on the Mini Mental State Examination
Exclusion Criteria:
- Evidence of any clinically significant functional impairment related to cardiovascular, pulmonary, metabolic, other neurologic or musculoskeletal disease criterial that would preclude participation in training
- Any medical condition that might require other medical or surgical treatment during the study period
- A history of brain surgery or placement of a deep brain stimulator
- Dyskinesias > grade 2 on the Unified Parkinson's Disease Rating Scale (UPDRS)
- Any uncorrected vision or hearing problems that may limit daily activities or communication
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Single Group
10 subjects with Parkinson's Disease receiving tPCS during the first session, treadmill walk, 7-10 days later (second session, and combined tPCS and treadmill 7-10 days week later (third session)
|
We will follow the procedure described by several investigators as safe and effective.
The participant will sit on a standard chair.
Two commercially available surface electrodes will be embedded in an elastic head cup.
Each electrode will be covered with a water soaked absorbent fabric.
One positive (+) electrode will be placed over the primary motor cortex (M1) and pre-motor areas.
One negative (-) electrode will be placed over the skin overlying the contra lateral supra-orbital region.
The electrodes will be connected via 2 leads to a battery powered direct current stimulator.
The stimulator will be programmed to deliver 0.975mA (peak 4mA) over 20 minutes.
The participant will walk on a treadmill for 20 minutes at the individually self-selected velocity determined at baseline.
Participants will have a combined session with CES while walking on the treadmill for 20 minutes at the individually self-selected velocity determined at baseline.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Stride Length
Time Frame: Data collection occurred before and immediately after each training session
|
Stride Length was measured in centimeters
|
Data collection occurred before and immediately after each training session
|
|
Gait Velocity
Time Frame: Data collection occurred before and immediately after each training session
|
Gait Velocity was measured in meters per second
|
Data collection occurred before and immediately after each training session
|
|
Cadence
Time Frame: Data collection occurred before and immediately after each training session
|
Cadence was measured in steps per minute
|
Data collection occurred before and immediately after each training session
|
|
Number of Steps to Regain Balance
Time Frame: Data collection occurred before and immediately after each training session
|
Steps to regain balance were measured by the number of steps needed to recover standing balance.
The steps were counted using a custom software of the motion capture system.
|
Data collection occurred before and immediately after each training session
|
|
First Step Length
Time Frame: Data collection occurred before and immediately after each training session
|
First step length was measured in meters from the starting position of the foot to the maximum displacement of the foot after the first step.
Measurements were taken separately for forward and backward first step.
|
Data collection occurred before and immediately after each training session
|
|
First Step Velocity
Time Frame: Data collection occurred before and immediately after each training session
|
First step velocity was measured in meters per second
|
Data collection occurred before and immediately after each training session
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Gad Alon, PhD, PT, University of Maryland, Baltimore
- Principal Investigator: Mark W Rogers, PhD, PT, University of Maryland, Baltimore
- Principal Investigator: Lisa Shulman, MD, Univeristy of Maryland, Baltimore
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2010
Primary Completion (Actual)
June 1, 2011
Study Completion (Actual)
June 1, 2011
Study Registration Dates
First Submitted
March 19, 2010
First Submitted That Met QC Criteria
April 8, 2010
First Posted (Estimate)
April 9, 2010
Study Record Updates
Last Update Posted (Actual)
October 30, 2019
Last Update Submitted That Met QC Criteria
October 28, 2019
Last Verified
October 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HP-00040670
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson's Disease
-
EicOsis Human Health Inc.University of California, Davis; Michael J. Fox Foundation for Parkinson's...RecruitingParkinson's Disease (PD)United States
-
University of Kansas Medical CenterNot yet recruitingParkinson's Disease (PD)United States
-
AbbVieRecruiting
-
University Hospital Schleswig-HolsteinUniversity of Kiel; University of Cologne; University Hospital, Bonn; Philipps...Not yet recruitingParkinson's Disease (PD)
-
InvicroMerck Sharp & Dohme LLCRecruitingParkinson's Disease | Parkinson's Disease (PD) | Parkinson's Disease (Disorder)United States
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
Assistance Publique - Hôpitaux de ParisFrance Parkinson AssociationUnknownHealthy Controls | Parkinson's Disease With LRRK2 Mutation | Parkinson's Disease Without LRRK2 MutationFrance
-
Guangzhou Henovcom Bioscience Co. Ltd.Frontage Clinical Services, Inc.Active, not recruitingParkinson's Disease (PD)United States
-
Universitätsklinikum Hamburg-EppendorfUniversity of TwenteRecruitingParkinson's Disease | Deep Brain StimulationGermany
-
Universitätsklinikum Hamburg-EppendorfUniversity of Oxford; University of TwenteRecruitingDeep Brain Stimulation | Parkinson's Disease (PD)Germany
Clinical Trials on Cranial Electric Stimulation (CES)
-
Xijing HospitalUnknown
-
Emory UniversityCongressionally Directed Medical Research ProgramsRecruitingGulf War SyndromeUnited States
-
University of Texas Southwestern Medical CenterTerminatedSleep Disorder | Cerebrovascular AccidentUnited States
-
The University of Texas Health Science Center,...CompletedOsteo Arthritis KneeUnited States
-
Brooke Army Medical CenterUnknownAnger | Irritability | Combat Related SymptomsUnited States
-
China Medical University HospitalNot yet recruitingDepression, AnxietyTaiwan
-
Walter Reed National Military Medical CenterCompletedPsychiatric Disorder
-
University of California, Los AngelesCompletedGeneralized Anxiety Disorder
-
ProofPilotFisher WallaceActive, not recruitingGeneralized Anxiety Disorder | Anxiety | Generalized AnxietyUnited States
-
The University of Texas Health Science Center at...CompletedDepression | PTSD | Anxiety | TBIUnited States